Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

NF1 affects around 1.7 million people worldwide, with about 70% being adults ... before AZ and its partner Merck were able to ...

On the other hand, Merck Foundation is also partnering the donation under ... “Adolescence can be a slippery and lonely road especially when you do not have supportive people to talk to, so it is nice ...

“We are delighted to learn of Timor-Leste’s success in eliminating LF as a public health problem,” said Allison Goldberg, president, Merck Foundation. “This achievement is a testament to the strength ...

AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from ... progressive genetic condition affecting an estimated 1.7 million people worldwide, approximately 70% ...

Merck published phase 3 data on Tuesday. Investigators in China, Europe and North America randomized 94 people with TGCT to ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)—which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

Green’s sister, Ragine Williams, 30, does DEI reporting, recruiting, and outreach for the technology firm SEI. She agreed that coming together with other women was inspiring, even if some may have ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

Winners received prestigious award in recognition of latest innovations in advancement in life sciences ...